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Results Sixty-four patients were treated in phase I. Doses 
of 100  mg cabozantinib plus 50  mg erlotinib, or 40  mg 
cabozantinib plus 150 mg erlotinib were determined to be 
MTDs. Diarrhea was the most frequent dose-limiting toxic-
ity and the most frequent AE (87.5% of patients). The ORR 
for phase I was 8.2% (90% CI 3.3–16.5). In phase II, one 
patient in the cabozantinib arm (N = 15) experienced a par-
tial response, for an ORR of 6.7% (90% CI 0.3–27.9), with 
no responses for cabozantinib plus erlotinib (N = 13). There 
was no evidence that co-administration of cabozantinib 
markedly altered erlotinib pharmacokinetics or vice versa.
Conclusions Despite responses with cabozantinib/erlo-
tinib in phase I, there were no responses in the combina-
tion arm of phase II in patients with acquired resistance to 
erlotinib. Cabozantinib did not appear to re-sensitize these 
patients to erlotinib.
Keywords Non-small cell lung cancer · Resistance · 
Cabozantinib · Erlotinib · Phase Ib/II · Combination 
therapy
Abstract 
Purpose Cabozantinib is a multi-kinase inhibitor that tar-
gets MET, AXL, and VEGFR2, and may synergize with 
EGFR inhibition in NSCLC. Cabozantinib was assessed 
alone or in combination with erlotinib in patients with pro-
gressive NSCLC and EGFR mutations who had previously 
received erlotinib.
Methods This was a phase Ib/II study (NCT00596648). 
The primary objectives of phase I were to assess the safety, 
pharmacokinetics, and pharmacodynamics and to deter-
mine maximum tolerated dose (MTD) of cabozantinib plus 
erlotinib in patients who failed prior erlotinib treatment. In 
phase II, patients with prior response or stable disease with 
erlotinib who progressed were randomized to single-agent 
cabozantinib 100  mg  qd vs cabozantinib 100  mg  qd and 
erlotinib 50 mg qd (phase I MTD), with a primary objec-
tive of estimating objective response rate (ORR).
These data were presented in part at the American Society 
for Clinical Oncology (ASCO) annual meeting in June 2010, 
Chicago, IL.
Electronic supplementary material The online version of this 
article (doi:10.1007/s00280-017-3283-z) contains supplementary 
material, which is available to authorized users.
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Introduction
Erlotinib and other epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitors (TKIs) are established 
first-line treatments for patients with non-small cell lung 
cancer (NSCLC) with activating mutations in EGFR. 
Despite response rates of 60–70% with EGFR TKIs in 
this patient population, the median progression-free sur-
vival (PFS) with these agents remains under 1 year [1] due 
to the development of acquired resistance [2, 3] through 
secondary resistance mutations (e.g., T790M) [4–8] and 
emergence of bypass signaling pathways such as vascu-
lar endothelial growth factor (VEGF) and MET [2, 7–11]. 
Data suggest that dual inhibition of the VEGF and EGFR 
pathways can delay the development of resistance to EGFR 
TKIs in the upfront setting [12] but may not overcome 
acquired resistance [13], whereas targeting MET has been 
shown to re-sensitize tumors resistant to EGFR TKIs in 
preclinical models [14].
Cabozantinib is a small-molecule inhibitor of multiple 
tyrosine kinases including MET, AXL, VEGF receptors 
(VEGFRs), and RET [15]. The drug has been approved by 
the US Food and Drug Administration (FDA) for the treat-
ment of progressive, metastatic medullary thyroid cancer 
[16, 17] and, more recently, for advanced renal cell carci-
noma after prior anti-angiogenic therapy [18, 19].
Preclinical studies in NSCLC suggest a potential for 
cabozantinib to re-sensitize tumors to EGFR inhibitors. The 
addition of cabozantinib to gefitinib had no notable impact 
on activity in a gefitinib-sensitive NSCLC cell line but re-
sensitized a gefitinib-resistant cell line [14]. Furthermore, 
the combination of cabozantinib and erlotinib demonstrated 
substantially increased anti-tumor activity over either agent 
administered alone in a MET-amplified NSCLC xenograft 
model resistant to EGFR inhibition.
Based on the hypothesis that the expression of MET and 
VEGF are mechanisms of acquired resistance to EGFR 
TKIs in NSCLC tumors [2, 9, 11, 20], the phase Ib/II 
study reported here tested whether cabozantinib, alone or 
in combination with continued EGFR inhibition, was tol-
erable and active in patients with advanced NSCLC who 
had progressed after benefiting from erlotinib therapy. The 
study was designed to first determine the maximum toler-
ated dose (MTD) of cabozantinib and erlotinib in com-
bination and then to assess the safety and clinical activ-
ity of the MTD combination compared with single-agent 
cabozantinib.
Patients and methods
This was a multicenter, phase Ib/II, open-label study 
of cabozantinib and erlotinib. All patients gave written 
informed consent for this trial according to international 
guidelines. The protocol was reviewed and treatment was 
monitored by institutional review boards at each participat-
ing institution, and the study adhered to the principles of the 
Guideline for Good Clinical Practice (International Confer-
ence on Harmonisation E6 Tripartite Guideline). The trial 
is registered at ClinicalTrials.gov (NCT00596648).
Eligible patients had histologically confirmed Stage 
IIIb or IV NSCLC. Patients were at least 18 years old, had 
adequate organ and marrow function with an absolute neu-
trophil count ≥1500/mm3, platelets ≥100,000/mm3, hemo-
globin ≥9  g/dL, bilirubin ≤1.5 times the upper limit of 
normal (ULN), serum creatinine ≤1.5 mg/dL or calculated 
creatinine clearance ≥60 mL/min, and alanine aminotrans-
ferase and aspartate aminotransferase ≤2.5 times ULN. 
Patients with uncontrolled brain metastases, clinically 
significant hemoptysis, and hematemesis were excluded. 
Patients were also excluded for the presence of cavitary 
pulmonary lesion(s), endobronchial lesion or a lesion abut-
ting a major blood vessel, pregnancy or lactation, serious 
intercurrent illness, uncontrolled hypertension [sustained 
blood pressure (BP) readings of >140  mmHg systolic or 
>90  mmHg diastolic], unhealed wounds from recent sur-
gery, or congestive heart failure, unstable angina, or clini-
cally significant cardiac arrhythmias within 3  months, or 
transient ischemic attack, stroke, or myocardial infarction 
within 6 months. Anti-cancer therapy, other than erlotinib 
(or gefitinib in phase II), was not allowed within 4 weeks 
prior to entry.
In addition to these eligibility criteria, patients enrolled 
in phase I must have failed prior treatment with erlotinib 
but tolerated erlotinib at a dose greater than or equal to the 
dose of the cohort in which they were assigned. Patients 
had to have an Eastern Cooperative Oncology Group 
(ECOG) performance status of ≤2.
For phase II, patients had to have measurable disease per 
Response Evaluation Criteria in Solid Tumors (RECIST) 
guidelines, version 1.0 [21] and an ECOG performance 
status of ≤1. Patients were also required to have had pro-
gressed during treatment with erlotinib after either an ini-
tial response or at least 6 months of stable disease. Patients 
were also required to have amylase and lipase <1.5 times 
the ULN. Patients were excluded for prior therapy with a 
VEGFR TKI, an investigational EGFR TKI, a MET inhibi-
tor, recent history (3 months) of radiation therapy other 
than to bones, or a history of idiopathic pulmonary fibrosis 
or interstitial lung disease.
Treatment plan and study design
In both phase I and II, erlotinib and cabozantinib were 
given orally (po) once daily (qd). Cabozantinib was 
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supplied as 20- and 80-mg capsules (expressed as the free-
base equivalent weight). Erlotinib 25-, 100-, and 150-mg 
tablets were available commercially. Screening was con-
ducted within 28 days before the first dose of study drug. 
Each cycle was 4 weeks (28 days).
Safety was assessed at frequent intervals by standard 
clinical and laboratory tests, physical examinations, and 
12-lead electrocardiograms. All adverse events (AEs) were 
graded according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI-CTCAE), 
version 3.0. Radiographic tumor assessments were con-
ducted at baseline (within 7 days before first dose in phase 
II) and every 8 weeks after the initiation of study treatment 
per RECIST guidelines, version 1.0 [21].
Phase I was a 3 + 3 dose escalation/de-escalation design 
in 2 parallel arms: Arm A maximized the dose of cabozan-
tinib [to a maximum dose of 140 mg qd (the single-agent 
MTD)] [22], and Arm B maximized the dose of erlotinib 
[to a maximum dose of 150  mg  qd (the label dose for 
NSCLC)] [23]. Primary objectives in phase I were to evalu-
ate the safety and tolerability of cabozantinib and erlotinib 
administered in combination, to determine a MTD of the 
combination, and to characterize the pharmacokinetic (PK) 
parameters of single-agent erlotinib (run-in period) and 
cabozantinib in combination with erlotinib. Exploratory 
objectives included the assessment of objective response 
rate (ORR). Erlotinib was administered as a single agent on 
days −14 to −1 (run-in period) at the dose used during sub-
sequent treatment with the combination. After PK evalua-
tion of erlotinib alone on day 1, cabozantinib was admin-
istered in combination with erlotinib qd in 28-day cycles.
Dose-limiting toxicity (DLT) was defined as any of the 
following that occurred during the first 28  days of treat-
ment: a treatment-emergent AE that warranted dose reduc-
tion or was of significant risk; non-hematologic signifi-
cant grade 3/4 toxicity, including grade 3 diarrhea despite 
prophylaxis and other optimal treatment; intolerable rash; 
grade 4 thrombocytopenia, grade 4 neutropenia of >5 days 
duration or grade 3/4 neutropenia with fever and docu-
mented infection; inability to take >75% of planned study 
dose owing to an AE; or inability to start Cycle 2 within 
28  days of planned start date because of an AE. Events 
clearly unrelated to either cabozantinib or erlotinib were 
not considered DLTs. The MTD was defined as a dose level 
below the maximum administered dose in which <30% 
of the total patients in the expanded cohort experienced a 
DLT.
For the initial dose cohort (Cohort 1), the dose levels 
for the combination were cabozantinib 60  mg qd + erlo-
tinib 150 mg qd (Table 1). The protocol was subsequently 
amended to allow for the 2 parallel-dose de-escalation/
dose escalation arms. In Arm A, the dose of erlotinib 
was reduced below the approved/label dose of 150 mg qd 
(initially to 100 mg qd) and the initial dose of cabozantinib 
was maintained at 60 mg qd and increased as tolerated in 
subsequent cohorts to a maximum of 140 mg qd. In Arm 
B, the dose of erlotinib was maintained at the approved/
label dose of 150 mg qd and the dose of cabozantinib was 
40  mg  qd. At the investigator’s discretion, patients could 
continue to receive cabozantinib after the DLT evaluation 
period either alone or in combination with erlotinib, pro-
vided that there was no evidence of progressive disease 
(PD) or unacceptable study drug-related toxicity.
Phase II was a Simon optimal 2-stage design in which 
patients were randomized in a 1:1 fashion to receive sin-
gle-agent cabozantinib at 100 mg qd or the combination of 
cabozantinib 100 mg qd plus erlotinib 50 mg qd based on 
the phase I Arm A MTD. The phase I MTD of Arm B was 
not further evaluated in phase II. Initial enrollment in each 
arm (Stage I) was estimated at 15 patients to ensure 12 were 
evaluable for response. If there was ≥1 responder in Stage 
I, enrollment could be expanded in that arm (Stage II). In 
phase II, the primary objective was to estimate the ORR. 
Secondary objectives included the evaluation of safety and 
tolerability, evaluation of PFS, and characterization of PK 
parameters of cabozantinib and erlotinib.
Crossover was permitted during phase II at the discre-
tion of the investigator. Patients treated in the single-agent 
cabozantinib arm who developed PD had the option to 
cross over to receive combination cabozantinib/erlotinib, 
whereas those receiving cabozantinib/erlotinib who experi-
enced PD had the option to cross over to single-agent cabo-
zantinib (at a dose greater than what they were receiving in 
the combination). Patients who crossed over could continue 
until they experienced unacceptable toxicity or treatment 
failure as defined by investigator assessment.
Pharmacokinetics
Blood samples for PK assessments were taken at prede-
termined intervals. In phase I, PK assessments were con-
ducted at 15 min before dose and then after dose at 30 min 
and 1, 2, 4, 8, and 24  h on day −1 and C2D1 (day 29); 
Table 1  Phase I dose-level cohorts
a All cabozantinib doses are expressed as the freebase equivalent 
weight
Cohort Initial dose (mg)a
1 60 cabozantinib, 150 erlotinib
2A 60 cabozantinib, 100 erlotinib
2B 40 cabozantinib, 150 erlotinib
3A 100 cabozantinib, 100 erlotinib
4A 100 cabozantinib, 50 erlotinib
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before dose and 4 h after dose on C2D15 (day 43); before 
dose approximately every 2 cycles (every 8 weeks) starting 
with C3D1 (day 57) to coincide with routine tumor assess-
ments; and at a 30-day post-treatment visit or study with-
drawal. In phase II, blood samples were collected 15 min 
before dose and 4  h after dose on C1D1, C1D15, C2D1, 
and C2D15, then every 2 cycles (8  weeks) starting with 
C3D1 to coincide with routine tumor assessments, ideally 
at the time of withdrawal from the trial.
Cabozantinib and erlotinib concentrations in plasma 
were determined using a validated liquid chromatogra-
phy–mass spectrometry method at Exelixis, Inc. All con-
centrations were reported in units of ng freebase/mL. The 
lower limit of quantification for both analytes was 0.5  ng 
freebase/mL. Data assembly was performed using S-Plus® 
8.0 for Windows (Enterprise Version, Tibco Software Inc., 
Palo Alto, CA). WinNonlin Professional 5.2 (Pharsight 
Corp., Mountain View, CA) was used for calculating the 
summary statistics and generating raw tables. Concentra-
tion–time profiles and other PK-related plots were gener-
ated using S-Plus Version 8.0 for Windows.
Statistical considerations
The safety population consists of all patients who received 
study treatment. The efficacy-measurable population was 
defined as patients with measurable disease at baseline. 
The safety population was used for all analyses except 
ORR, which used the efficacy-measurable population. Best 
overall response and ORR were summarized using fre-
quency counts and percentages, and the 90% confidence 
interval was computed using the exact binomial distri-
bution. Median duration of response and the associated 
90% confidence intervals (CIs) were calculated using the 
Kaplan–Meier method.
For patients who had a crossover in phase II, both effi-
cacy and safety data are summarized up to the time of 
crossover. For all other patients, study data are summarized 
up to 30 days after the last dose of study drug.
Statistical analyses of safety, PK, and pharmacodynamic 
data were performed with WinNonlin Enterprise, version 
5.0.1 (Pharsight Corp, Mountain View, CA), GraphPad 
Prism (version 4.02) software, SoftMaxPro GxP (version 
5), and/or SAS (version 9.1).
Results
A total of 65 patients were enrolled in phase I, and 64 
patients received combination treatment with cabozantinib/
erlotinib and were included in the analysis. One patient 
received erlotinib during the 14-day run-in period but with-
drew owing to PD before receiving cabozantinib. Baseline 
characteristics are summarized in Table 2. In phase I, the 
median patient age was 59.8 years (range 30–88 years), and 
44 patients (68.8%) were female. The majority of patients 
(43/64; 67.2%) were white; 17 (26.6%) were Asian. At 
baseline, all patients except 2 had an ECOG performance 
status of 0 or 1. The majority of patients (82.8%) had 
adenocarcinoma. All patients had metastatic disease at 
study entry for an average of >2  years from initial diag-
nosis, including 14% with brain metastases. The majority 
of patients in phase I had at least 3 anti-cancer regimens 
before enrolling in the study, and 63 patients (98.4%) had 
previously been treated with erlotinib.
In phase II, 28 patients received treatment with sin-
gle-agent cabozantinib (n = 15) or cabozantinib/erlo-
tinib (n = 13). The median age was 54.7  years (range 
36–74 years) in the cabozantinib arm and 64.8 years (range 
44–78  years) in the combination arm. Twelve patients 
(80.0%) in the cabozantinib arm and 7 patients (53.8%) in 
the combination arm were female. The majority of patients 
were white [10/15 (66.7%) cabozantinib arm and 8/13 
(61.5%) combination arm]; 4 (26.7%) in the cabozantinib 
arm and 3 (23.1%) in the combination arm were Asian. 
The majority of patients (93.3% receiving cabozantinib 
and 84.6% in the combination arm) had adenocarcinoma. 
All patients had metastatic disease at study entry, includ-
ing 25% with brain metastases. Similar to phase I, the mean 
years since the initial diagnosis of metastasis was >2 years, 
with the majority having received at least 3 prior anti-can-
cer regimens. An activating EGFR mutation was detected 
in 10 of the patients in the cabozantinib arm and 7 in the 
combination arm; EGFR mutation status was unknown for 
the remaining 11 patients.
Phase I MTD
DLTs from phase I of the trial are shown in Table 3. Fifteen 
patients experienced a DLT. Diarrhea was the most fre-
quently observed DLT across all cohorts (10 patients experi-
enced a DLT of diarrhea ranging from grade 2 to 3). Two of 
3 patients enrolled in Cohort 1 (60-mg cabozantinib/150-mg 
erlotinib) experienced a DLT of diarrhea (1 with grade 2 and 
1 with grade 3). The patient with grade 3 diarrhea also expe-
rienced grade 3 aspartate aminotransferase elevation and 
grade 3 palmar-plantar erythrodysesthesia syndrome (PPES). 
In Cohort 2A (60-mg cabozantinib/100-mg erlotinib), 5 of 
16 patients experienced DLTs: 4 patients with grade 3 diar-
rhea and 1 with grade 2 diarrhea. In Cohort 3A (100-mg 
cabozantinib/100-mg erlotinib), 5 of 15 patients experi-
enced a DLT: grade 3 diarrhea and grade 3 fatigue (n = 1), 
grade 3 fatigue (n = 1), grade 3 lipase elevation (n = 1), 
grade 3 hypertension (n = 1), and grade 3 hypokalemia 
(n = 1). The Cohort 3A dose exceeded the defined MTD. 
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A total of 14 patients were enrolled in Cohort 4A (100-mg 
cabozantinib/50-mg erlotinib), with no patients experienc-
ing a DLT. Based on the frequencies of DLTs in Arm A, the 
Cohort 4A dose level was declared the MTD of Arm A.
In Arm B, 17 patients were enrolled in Cohort 2B (40-
mg cabozantinib/150-mg erlotinib), 3 of whom experi-
enced DLTs: grade 3 diarrhea (n = 2) and grade 3 stomatitis 
(n = 1). The Cohort 2B dose level was determined to be the 
MTD of Arm B.
Safety and tolerability
Phase I
Treatment-emergent AEs (any grade) reported by at least 
15% of patients in phase I are summarized in supplemen-
tary Table  S1. The most common (>35%) AEs of any 
grade were diarrhea, decreased appetite, fatigue, nausea, 
rash, and weight decrease. Twenty patients (31.3%) had a 
≥30-mmHg increase in systolic BP from baseline, and 17 
patients (26.6%) had a ≥20-mmHg diastolic BP increase 
from baseline (supplementary Table S2). Grade 3/4 AEs 
were experienced by 87.5% of patients (Table  4). Diar-
rhea (45.3%), fatigue (21.9%), and hypokalemia (14.1%) 
were the most common grade 3/4 events. Twelve patients 
(18.8%) experienced an AE leading to drug discontinu-
ation, with diarrhea and PPES being the most common 
(10.9 and 3.1%, respectively).
There were 13 deaths within 30 days of the last dose of 
study treatment. One death was attributed to respiratory 
arrest and another to asystole/coronary artery atheroscle-
rosis and cardiac arrest; both were considered unrelated 
to study treatment. The remaining 11 deaths were attrib-
uted to PD. One patient who died of PD experienced a 
fatal pulmonary hemorrhage (day 26 after the last dose), 
which was assessed as possibly related to study treatment. 
Three additional grade 5 AEs reported in patients who 
died of PD were pneumonia, cardio-respiratory arrest, 
and respiratory failure, all unrelated to study treatment.
Table 2  Demographic and 
baseline characteristics: phase I 
and II (safety populations)
ECOG Eastern Cooperative Oncology Group
Phase I
(N = 64)
Phase II
Cabozantinib  
(N = 15)
Cabozantinib/erlotinib 
(N = 13)
Age (years)
Median (range) 59.8 (30–88) 54.7 (36–74) 64.8 (44–78)
Age category, n (%)
 18–<25 years 0 0 0
 25–<45 years 6 (9.4) 2 (13.3) 1 (7.7)
 45–<65 years 35 (54.7) 10 (66.7) 6 (46.2)
 ≥65 years 23 (35.9) 3 (20.0) 6 (46.2)
Sex, n (%)
 Male 20 (31.3) 3 (20.0) 6 (46.2)
 Female 44 (68.8) 12 (80.0) 7 (53.8)
ECOG performance status, n (%)
 0 26 (40.6) 5 (33.3) 2 (15.4)
 1 36 (56.3) 10 (66.7) 11 (84.6)
 2 1 (1.6) 0 0
 Missing 1 (1.6) 0 0
Race, n (%)
 Asian 17 (26.6) 4 (26.7) 3 (23.1)
 Black or African American 2 (3.1) 1 (6.7) 1 (7.7)
 White 43 (67.2) 10 (66.7) 8 (61.5)
 Not reported 1 (1.6) 0 1 (7.7)
 Other 1 (1.6) 0 0
Histology, n (%)
 Adenocarcinoma 53 (82.8) 14 (93.3) 11 (84.6)
 Squamous cell carcinoma 3 (4.7) 1 (6.7) 2 (15.4)
 Large cell carcinoma 1 (1.6) 0 0
 Other 7 (10.9) 0 0
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Phase II
The most commonly reported AEs (>35%) in phase II 
were fatigue, diarrhea, nausea, decreased appetite, and 
PPES (supplementary Table  S3). Differences were noted 
between treatment arms in the frequency of some AEs, 
including diarrhea (46.7% cabozantinib vs 84.6% cabo-
zantinib/erlotinib), dehydration (13.3 vs 46.2%), vomiting 
(20.0 vs 38.5%), cough (53.3 vs 7.7%), and constipation 
(40.0 vs 15.4%). Eleven patients (73.3%) in the cabozan-
tinib arm and 13 patients (100%) in the combination arm 
experienced at least 1 grade 3 or 4 AE (Table 5), with 53.3 
and 84.6% experiencing a treatment-related grade 3 or 4 
AE, respectively. Rates of grade 3/4 AEs differed between 
single-agent cabozantinib vs the combination for diarrhea 
(0 vs 30.8%), dehydration (0 vs 23.1%), and lymphopenia 
(0 vs 15.4%). Four patients (26.7%) in the cabozantinib arm 
and 3 (23.1%) in the combination arm had a ≥30-mmHg 
systolic BP increase from baseline; 8 patients (53.3%) and 
4 patients (30.8%), respectively, had a ≥20-mmHg diastolic 
BP increase from baseline (supplementary Table S4).
The rate of dose modification (dose interruption or reduc-
tion) due to AEs was 66.7% for cabozantinib and 69.2% for 
cabozantinib/erlotinib and was primarily due to PPES (33.3 
vs 23.1%) and diarrhea (6.7 and 38.5%). The most com-
mon reason for treatment discontinuation was PD (80.0% on 
cabozantinib and 46.2% on the combination). Discontinua-
tion due to AEs occurred in 2 (13.3%) patients receiving 
cabozantinib (fatigue and non-fatal hemorrhagic stroke) and 
5 patients (38.5%) receiving the combination (PPES, large 
intestine perforation, fatigue/diarrhea/weight loss, transient 
ischemic attack, and intracranial hemorrhage). Three patients 
in the cabozantinib arm died within 30  days of receiv-
ing their last dose of study drug, all from PD. There were 
2 deaths from PD and clinical deterioration within 30 days 
of last receiving the combination study dose that were not 
considered to be related to study treatment. The intracranial 
hemorrhage leading to discontinuation in the combination 
arm was considered treatment-related and was fatal.
Efficacy
Phase I
The efficacy-measurable population included 61 patients 
across the dose cohorts. Five patients experienced a partial 
response (PR) for an ORR of 8.2% [90% confidence inter-
val (CI) 3.3, 16.5%], with no apparent trend by dose level. 
The median PFS was 3.7 months (95% CI 3.2, 5.5 months).
The overall median duration of treatment for cabo-
zantinib was 3.6  months (range 0.1–36.0  months), or 
Table 3  Cabozantinib phase I DLTs
AST aspartate aminotransferase, DLT dose-limiting toxicity, PPES palmar-plantar erythrodysesthesia syndrome
a One event for each DLT unless otherwise specified
Cohort Dose (mg) N Patients with DLTs DLTsa
Cabozantinib Erlotinib
1 60 150 3 2 Diarrhea, grade 2
Diarrhea, grade 3
Increase AST, 
grade 3
PPES, grade 3
2A 60 100 16 5 Diarrhea, grade 3 
(n = 4)
Diarrhea, grade 2
2B 40 150 17 3 Diarrhea, grade 3 
(n = 2)
Mucositis, grade 3
3A 100 100 15 5 Hypokalemia, 
grade 3
Hypertension, 
grade 3
Diarrhea, grade 3
Fatigue, grade 3 
(n = 2)
Lipase, grade 3
Epigastric pain, 
grade 3
4A 100 50 14 0 N/A
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approximately 4 cycles of study treatment. The majority 
of patients (57.8%) were treated until disease progression 
per RECIST guidelines, version 1.0. Cumulatively, there 
were 45 patients (70.3%) who were on study treatment for 
≥8 weeks (2 cycles) and 31 patients (48.4%) on study treat-
ment for ≥16 weeks (4 cycles). One patient with prolonged 
stable disease and 1 patient with prolonged objective 
response (each with a PFS duration of >1000 days and on 
study treatment >35 cycles) were eventually transitioned 
onto a cabozantinib maintenance protocol and continued on 
therapy for an additional 18+ months.
Phase II
One of 15 patients in the single-agent cabozantinib arm 
achieved a confirmed PR for an ORR of 6.7% (90% CI 
0.3, 27.9%), whereas there were no responses in the cabo-
zantinib/erlotinib arm. The median PFS was 1.9  months 
(95% CI 1.6, 7.1  months) for the cabozantinib arm and 
3.9 months (95% CI 1.5, 7.3 months) for the combination 
arm.
The overall median duration of treatment for cabozan-
tinib (not including treatment after crossover) was 2.1 
months (range 0.2–16.6 months) or approximately 2 cycles 
of study treatment in both treatment arms. Cumulatively, 
there were 18 patients (64.3%) who were on study treat-
ment for ≥8 weeks (2 cycles), 12 patients (42.9%) on study 
treatment for ≥12 weeks (3 cycles), and 9 patients (32.1%) 
on study treatment for ≥16 weeks (4 cycles).
Eight patients crossed over from cabozantinib to cabo-
zantinib/erlotinib after experiencing PD. The patient who 
achieved a PR with single-agent cabozantinib progressed 
and crossed over to receive cabozantinib/erlotinib (PFS 
duration of 16.6  months prior to crossover) and subse-
quently transitioned to the cabozantinib maintenance pro-
tocol continuing treatment for an additional 18+ months. 
Despite the PR in the single-agent cabozantinib arm, 
expansion of the arm did not proceed owing to logistical 
issues and prioritization of resources and not because of 
unexpected safety concerns or lack of efficacy.
Pharmacokinetics
During phase Ib of the study, available PK results were 
analyzed for each dosing cohort at the time of the cohort 
review committee meetings to assess for any apparent 
drug–drug interaction between cabozantinib and erlotinib. 
Co-administration of cabozantinib (in a dose range of 
40–100 mg) and erlotinib (in a dose range of 50–150 mg) 
had no apparent effect on plasma area under the curve of 
each agent compared with that agent administered alone.
Formal PK analysis was conducted in phase II of the 
study. In phase II, with all patients in the single-agent arm 
receiving cabozantinib 100 mg po qd, the mean ± standard 
deviation (SD) pre-dose plasma concentration of cabozan-
tinib was 996 ± 513 ng/mL and 846 ± 335 ng/mL on day 15 
(C1D15) and day 29 (C2D1), respectively. Dose normaliza-
tion of these means (i.e., dividing by 100 mg) resulted in 
values that were generally consistent with dose-normalized 
results seen for other cabozantinib studies [22]. Steady 
state was reached by about day 15. Approximately fourfold 
plasma accumulation of cabozantinib was observed in this 
study based on the day 29:day 1 concentration at 4 h post-
dose ratio, which was generally consistent with the results 
Table 4  Treatment-emergent grade 3 or 4 adverse events reported by 
≥5% of patients: phase I (safety population)
Preferred term, n (%) N = 64
Any treatment-emergent adverse event 56 (87.5)
Diarrhea 29 (45.3)
Fatigue 14 (21.9)
Hypokalemia 9 (14.1)
Dyspnea 7 (10.9)
Pneumonia 6 (9.4)
Decreased appetite 5 (7.8)
Hypophosphatemia 5 (7.8)
Hypertension 5 (7.8)
Pulmonary embolism 5 (7.8)
Weight decreased 5 (7.8)
Dehydration 4 (6.3)
Hyponatremia 4 (6.3)
Hypoxia 4 (6.3)
Pain 4 (6.3)
Back pain 3 (4.7)
Hypomagnesemia 3 (4.7)
Blood potassium decreased 3 (4.7)
Lipase increased 3 (4.7)
Renal failure acute 3 (4.7)
Palmar-plantar erythrodysesthesia syndrome 3 (4.7)
Thrombocytopenia 3 (4.7)
Table 5  Treatment-emergent grade 3 or 4 adverse events in ≥2 
patients: phase II (safety population)
Preferred term, n (%) Cabozantinib 
(N = 15)
Cabozantinib  
+ erlotinib 
(N = 13)
Hypertension 2 (13.3) 1 (7.7)
Hyponatremia 2 (13.3) 1 (7.7)
Fatigue 2 (13.3) 1 (7.7)
Hypokalemia 1 (6.7) 2 (15.4)
Diarrhea 0 4 (30.8)
Dehydration 0 3 (23.1)
Lymphopenia 0 2 (15.4)
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reported in other studies. Plasma concentrations of cabo-
zantinib were maintained over an extended dosing period 
(through study day 60) for both the single-agent cabozan-
tinib and cabozantinib/erlotinib arms during phase II (data 
not shown). No marked difference in plasma cabozantinib 
concentration was seen between the cabozantinib vs cabo-
zantinib/erlotinib arms; there was no evidence to suggest 
that co-administration of erlotinib markedly altered cabo-
zantinib PK.
Interpatient variability (coefficient of variance, CV%) in 
erlotinib pre-dose concentrations (79.8 and 59.8% on day 
15 and day 29, respectively) was consistent with the pub-
lished values [24, 25]. Furthermore, the mean dose-nor-
malized erlotinib pre-dose concentration on day 15 (i.e., 
355 ng/mL for 50-mg erlotinib = 7.1 ng/mL/mg) was gen-
erally consistent with the published results for steady-state 
erlotinib minimum concentration (Cmin), in which a mean 
value of approximately 7.5 ng/mL/mg was observed across 
the 50–200  mg erlotinib dose groups on day 24 [24, 25]. 
Taken together, there was no evidence to suggest that co-
administration of cabozantinib markedly altered erlotinib 
PK.
Discussion
Multiple strategies to overcome resistance to EGFR TKIs 
have been explored over the past decade. The multi-TKI 
cabozantinib, with potent MET/AXL/VEGFR2 blockade, 
seemed an ideal compound alone or in combination with 
erlotinib to overcome secondary erlotinib resistance. As 
discovered in this phase Ib/II trial, however, this strategy 
resulted in increased frequency of overlapping toxicities, 
most notably, diarrhea. Nevertheless, phase Ib established 
2 combination MTDs to bring forward into future tri-
als. Dose escalation was explored in 2 parallel arms, each 
maximizing doses of cabozantinib (Arm A) and erlotinib 
(Arm B). Dose escalation was limited predominantly by 
diarrhea. Eventually, the MTD for the combination of cabo-
zantinib/erlotinib in Arm A was determined to be 100-mg 
cabozantinib/50-mg erlotinib (maximizing the cabozantinib 
dose) and the MTD in Arm B was determined to be 40-mg 
cabozantinib/150-mg erlotinib (maximizing the erlotinib 
dose). These MTDs were below the maximum planned 
doses, but were based on the toxicities observed in this 
trial. Other toxicities were as expected for a combination of 
EGFR and VEGFR inhibition, including PPES and hyper-
tension. PK analysis revealed no evidence that co-adminis-
tration of the agents markedly altered the PK of either drug, 
despite both being CYP3A4 substrates.
Phase II evaluated single-agent cabozantinib at 100 mg 
and the combination MTD of Arm A from phase I (100-mg 
cabozantinib/50-mg erlotinib). Although there was a PR in 
the single-agent cabozantinib arm of phase II, expansion of 
that arm into the second stage of enrollment did not occur 
for logistical reasons, preventing further assessment of sin-
gle-agent activity. Toxicity was as expected in phase II. The 
most frequent grade 3/4 AEs were hypertension, hypona-
tremia, and fatigue for the cabozantinib arm and diarrhea 
and dehydration for the cabozantinib/erlotinib arm. The 
most frequent AE leading to study drug modification in the 
cabozantinib arm was PPES, whereas diarrhea, dehydra-
tion, and PPES were the most frequent AEs leading to dose 
modification in the combination arm.
One treatment-related death occurred in the phase II 
cabozantinib/erlotinib arm from an intracranial hemor-
rhage. Two other patients experienced non-fatal central 
nervous system events, 1 with a transient ischemic attack 
(combination arm) and 1 with a hemorrhagic stroke (cabo-
zantinib). In phase Ib, 1 patient who died of PD had a 
potential treatment-related toxicity of pulmonary hemor-
rhage nearly a month after study drug discontinuation. 
Severe hemorrhage is a rare but potentially fatal complica-
tion that has been reported with cabozantinib in other clini-
cal studies; thrombotic events have also been reported [26]. 
Thus, caution is warranted with this combination.
The ORR for phase I was 8.2% (5 of 61 patients) with 
no apparent dose–response trend among the combination 
cohorts, but there were no PRs in the 13 patients rand-
omized to the combination arm in phase II. There was 1 
responder out of 15 (6.7%) in the phase II single-agent 
cabozantinib arm. Almost all patients enrolled in this 
study were previously treated with erlotinib; however, only 
patients enrolled in phase II were required to have previ-
ously experienced a response or prolonged stable disease 
and subsequently progressed during erlotinib treatment 
(acquired resistance). The addition of cabozantinib to erlo-
tinib in the phase II combination arm did not restore sen-
sitivity to EGFR TKI therapy, although this arm was rela-
tively small.
The limited efficacy of the cabozantinib/erlotinib combi-
nation in phase II is perhaps not surprising given the infor-
mation that has emerged since the initiation of this trial 
implicating secondary mutations in EGFR (e.g., T790M) as 
a more common resistance mechanism than MET amplifi-
cation (the rationale for this study) [7]. Other trials focused 
on MET inhibition to prevent or delay EGFR TKI resist-
ance have also had limited success [27]. Thus, a study 
limitation is the lack of routine testing for EGFR-activating 
mutations, which was not standard at the time this trial was 
conducted (first patient enrolled February 12, 2008). We 
did not verify patient EGFR-activating mutation status, as 
patients were selected based on clinical criteria of response 
to EGFR TKI (a reasonable surrogate) or at least 6 months 
of stable disease on erlotinib before progression, which 
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may have allowed a significant number of patients without 
true EGFR-activating mutations onto the trial.
As the patients enrolled in the current study were likely 
heterogeneous with respect to EGFR mutation status and 
mechanisms of resistance to prior EGFR TKI treatment, it is 
difficult to draw firm conclusions about the clinical activity of 
cabozantinib in EGFR mutant NSCLC. The responses seen 
with the combination in phase I and the response seen with 
single-agent cabozantinib in phase II supported additional 
investigations of cabozantinib in NSCLC. A randomized 
discontinuation trial of cabozantinib in unselected patients 
with NSCLC reported a single-agent response rate of 10% 
[28]. The California Cancer Consortium completed a phase II 
study of 37 patients with NSCLC and an EGFR mutation who 
had progressed on prior EGFR TKI therapy using the com-
bination dose of 40 mg qd for cabozantinib and 150 mg qd 
for erlotinib [29]. The reported toxicities in this phase II 
trial were similar to those reported in the current study. The 
response rate was 5.4% and the disease control rate (defined 
as PR or SD ≥8 weeks) was 67.6%. Furthermore, the role of 
VEGF inhibition to delay erlotinib resistance in patients with 
EGFR mutation NSCLC recently received renewed inter-
est with publication of a positive phase II trial looking at the 
addition of the VEGF antibody bevacizumab to single-agent 
erlotinib as a first-line strategy [12]. Taken together, further 
exploration of cabozantinib in combination with erlotinib in 
patients with EGFR mutations is warranted, possibly select-
ing patients based on MET expression.
Cabozantinib, with and without erlotinib, also holds 
promise in other subsets of NSCLC. Activity with single-
agent cabozantinib has been reported in a small series of 
patients with NSCLC with translocations in ROS1 [30] or 
RET mutations [31]. Specific trials in these patient popu-
lations are ongoing or planned. A phase II trial (E1512) 
focused on patients with EGFR wildtype disease rand-
omized patients to either erlotinib alone (150  mg po qd), 
cabozantinib alone (60  mg po qd), or in combination 
(150  mg erlotinib/40  mg cabozantinib), with crossover to 
the combination for those with PD on either single agent. 
The study showed a significant improvement in PFS and 
OS with the cabozantinib-containing arms compared with 
single-agent erlotinib; follow-up studies are currently in 
development [32]. Correlative analyses of outcomes with 
MET, KRAS, and other known driver mutations are ongo-
ing. These additional studies will provide further insight 
into a potential role for cabozantinib in the treatment of 
NSCLC.
Acknowledgements This study was supported by Exelixis Inc. 
(South San Francisco, CA) and was also supported in part by CTSA 
award number UL1 RR025744 (STANFORD CTRU) from the 
National Center for Research Resources, National Institutes of Health. 
Editorial assistance was provided by Michael Raffin (Fishawack Com-
munications, Conshohocken, PA), which was supported by Exelixis.
Compliance with ethical standards 
Conflict of interest H.A. Wakelee received consultant fees and 
honoraria from Peregrine, Acea, Pfizer, Helsinn, Genentech (uncom-
pensated), and received research/grants from Clovis, Exelixis, As-
traZeneca/MedImmune, Genentech/Roche, BMS, Gilead, Novartis, 
Xcovery, Pfizer, Celgene, Pharmacyclics, and Lilly. S. Gettinger, D.S. 
Subramaniam, J. Leach, and M. Wax have no conflicts of interest to 
report. J. Engelman is an employee of Novartis and has received eq-
uity in Novartis. P. A. Jänne has received consulting fees for drug de-
velopment from AstraZeneca, Boehringer Ingleheim, Pfizer, Roche, 
Genentech, ARIAD Pharmaceuticals, Ignyta, and LOXO Oncology; 
sponsored research funding from AstraZeneca, PUMA, and Daiichi-
Sankyo; and post-marketing royalties on DFC-owned intellectual 
property on EGFR mutations licensed to Lab Corp. H. West received 
consultant fees and honoraria from AstraZeneca, Boehringer Ingle-
heim, Genentech/Roche, and TrovaGene. Y. Yaron is an employee of 
Exelixis and owns stock and stock options in Exelixis. D. R. Miles was 
an employee of Exelixis and received stock from Exelixis when the 
study was underway. P.N. Lara received consultant fees from Exelixis.
Ethical approval All procedures performed in studies involving 
human participants were in accordance with the ethical standards of 
the institutional and/or national research committee and with the 1964 
Helsinki declaration and its later amendments or comparable ethical 
standards.
Informed consent Informed consent was obtained from all individ-
ual participants included in the study.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Rosell R, Carcereny E, Gervais R et  al (2012) Erlotinib ver-
sus standard chemotherapy as first-line treatment for European 
patients with advanced EGFR mutation-positive non-small-cell 
lung cancer (EURTAC): a multicentre, open-label, randomised 
phase 3 trial. Lancet Oncol 13(3):239–246
 2. Engelman JA, Zejnullahu K, Mitsudomi T et  al (2007) MET 
amplification leads to gefitinib resistance in lung cancer by acti-
vating ERBB3 signaling. Science 316(5827):1039–1043
 3. Jackman D, Pao W, Riely GJ et al (2010) Clinical definition of 
acquired resistance to epidermal growth factor receptor tyros-
ine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 
28(2):357–360
 4. Balak MN, Gong Y, Riely GJ et  al (2006) Novel D761Y and 
common secondary T790M mutations in epidermal growth fac-
tor receptor-mutant lung adenocarcinomas with acquired resist-
ance to kinase inhibitors. Clin Cancer Res 12(21):6494–6501
 5. Kobayashi S, Boggon TJ, Dayaram T et al (2005) EGFR muta-
tion and resistance of non-small-cell lung cancer to gefitinib. N 
Engl J Med 352(8):786–792
 6. Gazdar AF (2009) Activating and resistance mutations of EGFR 
in non-small-cell lung cancer: role in clinical response to EGFR 
tyrosine kinase inhibitors. Oncogene 28 Suppl 1:S24-31
932 Cancer Chemother Pharmacol (2017) 79:923–932
1 3
 7. Sequist LV, Waltman BA, Dias-Santagata D et al (2011) Geno-
typic and histological evolution of lung cancers acquiring resist-
ance to EGFR inhibitors. Sci Transl Med 3(75):75ra26
 8. Yu HA, Arcila ME, Rekhtman N et al (2013) Analysis of tumor 
specimens at the time of acquired resistance to EGFR-TKI ther-
apy in 155 patients with EGFR-mutant lung cancers. Clin Cancer 
Res 19(8):2240–2247
 9. Yano S, Wang W, Li Q et  al (2008) Hepatocyte growth factor 
induces gefitinib resistance of lung adenocarcinoma with epi-
dermal growth factor receptor-activating mutations. Cancer Res 
68(22):9479–9487
 10. Rho JK, Choi YJ, Kim SY et al (2014) MET and AXL inhibi-
tor NPS-1034 exerts efficacy against lung cancer cells resistant 
to EGFR kinase inhibitors because of MET or AXL activation. 
Cancer Res 74(1):253–262
 11. Tang Z, Du R, Jiang S et al (2008) Dual MET-EGFR combinato-
rial inhibition against T790M-EGFR-mediated erlotinib-resistant 
lung cancer. Br J Cancer 99(6):911–922
 12. Seto T, Kato T, Nishio M et  al (2014) Erlotinib alone or with 
bevacizumab as first-line therapy in patients with advanced non-
squamous non-small-cell lung cancer harbouring EGFR muta-
tions (JO25567): an open-label, randomised, multicentre, phase 
2 study. Lancet Oncol 15(11):1236–1244
 13. Herbst RS, Ansari R, Bustin F et  al (2011) Efficacy of bevaci-
zumab plus erlotinib versus erlotinib alone in advanced non-
small-cell lung cancer after failure of standard first-line chemo-
therapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. 
The Lancet 377(9780):1846–1854
 14. Janne PA, Wax M, Leach J, Engelman J (2008) Targeting MET 
with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) 
resistance in NSCLC: impact of preclinical studies on clinical 
trial design. EJC Supplements 6(12): 174 (Abstract 552)
 15. Yakes FM, Chen J, Tan J et al (2011) Cabozantinib (XL184), a 
novel MET and VEGFR2 inhibitor, simultaneously suppresses 
metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 
10(12):2298–2308
 16. Viola D, Cappagli V, Elisei R (2013) Cabozantinib (XL184) for 
the treatment of locally advanced or metastatic progressive med-
ullary thyroid cancer. Future Oncol 9(8):1083–1092
 17. Bentzien F, Zuzow M, Heald N et al (2013) In vitro and in vivo 
activity of cabozantinib (XL184), an inhibitor of RET, MET, 
and VEGFR2, in a model of medullary thyroid cancer. Thyroid 
23(12):1569–1577
 18. Choueiri TK, Escudier B, Powles T et  al (2015) Cabozantinib 
versus everolimus in advanced renal-cell carcinoma. N Engl J 
Med 373(19):1814–1823
 19. Choueiri TK, Escudier B, Powles T et  al (2016) Cabozantinib 
versus everolimus in advanced renal cell carcinoma (METEOR): 
final results from a randomised, open-label, phase 3 trial. Lancet 
Oncol 17(7):917–927
 20. Masuya D, Huang C, Liu D et  al (2004) The tumour-stro-
mal interaction between intratumoral c-Met and stromal 
hepatocyte growth factor associated with tumour growth and 
prognosis in non-small-cell lung cancer patients. Br J Cancer 
90(8):1555–1562
 21. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guide-
lines to evaluate the response to treatment in solid tumors. 
European Organization for Research and Treatment of Cancer, 
National Cancer Institute of the United States, National Cancer 
Institute of Canada. J Natl Cancer Inst 92(3):205–216
 22. Kurzrock R, Sherman SI, Ball DW et  al (2011) Activity 
of XL184 (Cabozantinib), an oral tyrosine kinase inhibi-
tor, in patients with medullary thyroid cancer. J Clin Oncol 
29(19):2660–2666
 23. Tarceva (erlotinib) (2016) Prescribing information. Genentech, 
South San Francisco
 24. Hidalgo M, Siu LL, Nemunaitis J et al (2001) phase I and phar-
macologic study of OSI-774, an epidermal growth factor recep-
tor tyrosine kinase inhibitor, in patients with advanced solid 
malignancies. J Clin Oncol 19(13):3267–3279
 25. Hidalgo M, Bloedow D (2003) Pharmacokinetics and phar-
macodynamics: maximizing the clinical potential of Erlotinib 
(Tarceva). Semin Oncol 30(3 Suppl 7):25–33
 26. Elisei R, Schlumberger MJ, Muller SP et  al (2013) Cabozan-
tinib in progressive medullary thyroid cancer. J Clin Oncol 
31(29):3639–3646
 27. Spigel DR, Edelman MJ, O’Bryne K et al (2014) Onartuzumab 
plus erlotinib versus erlotinib in previously treated stage IIIb or 
IV NSCLC: results from the pivotal phase III randomized, mul-
ticenter, placebo-controlled METLung (OAM4971g) global trial. 
J Clin Oncol 32(suppl; abstr 8000):5s
 28. Hellerstedt BA, Edelman G, Vogelzang NJ et  al (2012) Activ-
ity of cabozantinib (XL184) in metastatic NSCLC: results from 
a phase II randomized discontinuation trial (RDT). J Clin Oncol 
30(suppl; abstr 7514)
 29. Reckamp KL, P.H. F, Mack PC et  al (2014) Phase II trial of 
XL184 (cabozantinib) plus erlotinib in patients (pts) with 
advanced EGFR-mutant non-small cell lung cancer (NSCLC) 
with progressive disease (PD) on epidermal growth factor recep-
tor (EGFR) tyrosine kinase inhibitor (TKI) therapy: a Califor-
nia Cancer Consortium phase II trial (NCI 9303). J Clin Oncol 
32(suppl; abstr 8014)
 30. Katayama R, Kobayashi Y, Friboulet L et al (2015) Cabozantinib 
Overcomes Crizotinib Resistance in ROS1 Fusion-Positive Can-
cer. Clin Cancer Res 21(1):166–174
 31. Mukhopadhyay S, Pennell NA, Ali SM et  al (2014) RET-rear-
ranged lung adenocarcinomas with lymphangitic spread, psam-
moma bodies, and clinical responses to cabozantinib. J Thorac 
Oncol 9(11):1714–1719
 32. Neal JW, Dahlberg SE, Wakelee HA et al (2016) Erlotinib, cabo-
zantinib, or erlotinib plus cabozantinib as second-line or third-
line treatment of patients with EGFR wild-type advanced non-
small-cell lung cancer (ECOG-ACRIN 1512): a randomised, 
controlled, open-label, multicentre, phase 2 trial. Lancet Oncol. 
doi:10.1016/S1470-2045(16)30561-7
